loading page

A nomogram with Ki-67 in the prediction of postoperative recurrence and death for glioma
  • +2
  • Fengfeng Li,
  • Dongyuan Wang,
  • Nana Wang,
  • Linlin Wu,
  • Bo Yu
Fengfeng Li
Tengzhou Central People's Hospital
Author Profile
Dongyuan Wang
The Affiliated Tengzhou Central People's Hospital of Xuzhou Medical University
Author Profile
Nana Wang
The Affiliated Tengzhou Central People's Hospital of Xuzhou Medical University
Author Profile
Linlin Wu
The Affiliated Tengzhou Central People's Hospital of Xuzhou Medical University
Author Profile
Bo Yu
The Affiliated Tengzhou Central People's Hospital of Xuzhou Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Background: To evaluate the predictive value of a nomogram with Ki-67 in overall and disease-free survival in glioma patients. Methods: A total of 76 patients diagnosed with glioma were enrolled. The baseline data and followups were retrospectively collected from medical records. The associations between Ki-67 and survival status were examined using log-rank test, univariate and multivariate Cox proportional hazard regression models. Calibrations were performed to validate the established nomograms. Results: Ki-67 negative group showed a longer OS survival time and a longer PFS survival time with log-rank test (x2=16.101, P<0.001 and x2=16.961, P<0.001). Age older than 50 years (HR=2.074, 95% CI: 1.097-3.923), abnormal treatment (HR=2.932, 95% CI: 1.343-6.403) and Ki-67 positive (HR=2.722, 95% CI: 1.097-6.755) were the independent predictive factors of death. High grade pathology (HR=2.453, 95% CI: 1.010-5.956) and Ki-67 positive (HR=2.200, 95% CI: 1.043-4.639) were the independent predictive factors of recurrence. The C-index for the nomogram of OS and PFS were 0.745 and 0.723, respectively. The calibration results showed that the nomogram could predict the overall and disease-free 1-year survival of glioma patients. Conclusion: The nomograms with Ki-67 as independent risk factor for OS and PFS could provide clinical consultation in the treatment and follow-up of malignant glioma.
06 Nov 2023Submitted to Cancer Reports
08 Nov 2023Submission Checks Completed
08 Nov 2023Assigned to Editor
08 Nov 2023Review(s) Completed, Editorial Evaluation Pending
11 Nov 2023Reviewer(s) Assigned